Healthcare resource utilisation associated with skeletal‐related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study

Abstract

University of Bristol -Explore Bristol Research General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. this was most likely for RB (74.8%) and least likely for non-vertebral fracture (50.0%).Conclusions: All SREs were associated with substantial HRU; therefore, preventing SREs in MM will reduce the economic and resource burden on healthcare systems. K E Y W O R D Sadvanced cancer, bone lesions, healthcare resource utilisation, multiple myeloma, observational research, skeletal-related eventsThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

“…the trial SRE rates were multiplied by the rate ratio) 38 . Although a real-world SRE adjustment factor lower than 2.84 has previously been reported for SREs in solid tumors 36 , the adoption of 2.84 in the base case for this analysis is consistent with the available (albeit limited) evidence of SRE rates in MM 37,38 .…”

“…Real-world studies have found that the SRE rate for zoledronic acid was higher than those reported from clinical trials 36,37 . To account for this difference, a real-world adjustment relative rate ratio of 2.84 was applied to the clinical trial results (i.e.…”

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy

“…f Costs inflated using the health consumer index (þ13%) 55 . g Micro-costing approach using HRU reported by Ashcroft et al 10 and published unit costs (Official Gazette of the Italian Republic no. 23, January 28, 2013general series [supplemento ordinario 8, allegato 1 e 3]).…”

“…Importantly, SREs are associated with a poor prognosis, and with substantial morbidity, pain, and reduced quality-oflife 3,[7][8][9] . In addition to their negative impact on patients, SREs are associated with increased healthcare resource use (HRU), including emergency department visits, hospitalization, outpatient clinic attendance, and analgesic use 6,[10][11][12][13] ; therefore, SREs can increase MM direct healthcare costs by $75% vs those without SREs 12 . Furthermore, multiple SREs, which patients often experience, are associated with greater HRU and costs than isolated events 11,12 .…”

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

“…They may lead to increased mortality in patients with MM [11][12][13], and contribute towards disability and reduced health-related quality of life [5,14], although individuals with bone complications may have more advanced disease [15,16]. Management of bone complications is also associated with considerable healthcare resource use [6,[17][18][19]. Although outcomes for patients with MM continue to improve owing to the expanding number of effective treatments available [20,21], bone complications remain a significant problem [8].…”